Anacetrapib reduces risk of serious cardiovascular events in high risk patients (REVEAL)

Comments Off on Anacetrapib reduces risk of serious cardiovascular events in high risk patients (REVEAL)
Anacetrapib, an inhibitor of cholesteryl ester transfer protein (CETP) activity, lowers the risk of heart attack and related cardiovascular complications in patients receiving intensive statin treatment, according to late-breaking results from the REVEAL trial presented today in a Hot Line Session at ESC Congress and published in the NEJM.

mindsculptme

Related Posts

Create Account



Log In Your Account